The result of a DXRX collaboration has recently been presented at the ESMO-Targeted Anticancer Therapies Congress 2023. The aim of the study was to determine reproducibility and comparability of CLDN18 testing in gastric cancer.
- Comparing the specificy, accuracy, sensitivity and precision of three CLDN19 antibodies on multiple staining platforms for the detection of CLDN18.2 in GC by IHC across 27 global laboratories.
- The findings from this study will provide data to support laboratories when implementing CLDN18 biomarker testing for GC.
Diaceutics would like to extend our thanks to everyone who engaged in this successful collaboration.